Enanta

RSV

Biotech

Enanta sees RSV drug fail phase 2b but finds positives

With some analyses generating signs of efficacy, the biotech made the case that the data support further development of the direct-acting antiviral.

Nick Paul Taylor Sep 29, 2025 8:05am

Rendered image of a respiratory syncytial virus

Enanta RSV antiviral reduces viral load in ph. 2 pediatric trial

Dec 9, 2024 9:35am

RSV virus

Enanta's RSV antiviral crushes viral load in challenge study

Sep 26, 2024 7:43am

RSV virus

Enanta halts work on joint hMPV-RSV drug to extend cash to 2027

Nov 21, 2023 8:30am

covid test negative test tube COVID-19 pandemic

Enanta makes the case for COVID-19 antiviral's mixed data

May 9, 2023 9:47am

Where are they now? Tracking down 2012's Fierce 15

Aug 29, 2022 3:00am